We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > S1P

News List

Bristol Myers Squibb Receives European Commission Approval of Zeposia for Ulcerative Colitis AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb today announced that the European Commission has granted a Marketing Authorization for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response...
EC approve Zeposia® to treat ulcerative colitis EuropeanPharmaceuticalReview
November 29, 2021
The European Commission (EC) has has granted a marketing authorisation for Zeposia® (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis (UC)...
Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel S1P Receptor Modulator americanpharmaceuticalreview
March 12, 2019
Bridge Medicines announced an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator.